Li Jiejie, Wang Yongjun
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.
China National Clinical Research Center for Neurological Diseases, Beijing, 100050, China.
Neurosci Bull. 2016 Oct;32(5):463-8. doi: 10.1007/s12264-016-0038-5. Epub 2016 Jun 1.
Minor stroke and transient ischemic attack (TIA) are common disorders with a high rate of subsequent disabling stroke, so the early recognition and management of minor stroke and TIA is of great importance. At the moment, the diagnosis of these disorders is based on neurologic deficits in a stroke-clinician's examination of the patient, supplemented by the results of acute brain imaging. However, high variability in TIA diagnosis has been reported between physicians, even trained vascular neurologists, and image-based diagnostic confirmation is not always readily available. Some patients still have ischemic events despite sustained standard secondary preventive therapy. Blood biomarkers are promising to aid in the diagnosis, risk stratification, and individual treatment of minor stroke and TIA. Some studies are being conducted in this field. This mini-review aims to highlight potential biomarkers for diagnosis and those helpful in predicting the risk of future stroke and the selection of treatment.
轻度中风和短暂性脑缺血发作（TIA）是常见疾病，后续发生致残性中风的几率很高，因此早期识别和处理轻度中风和TIA非常重要。目前，这些疾病的诊断基于中风临床医生对患者的神经系统检查结果中的神经功能缺损，并辅以急性脑成像结果。然而，据报道，即使是训练有素的血管神经科医生，不同医生之间对TIA的诊断也存在很大差异，而且基于图像的诊断确认并非总能轻易获得。尽管进行了持续的标准二级预防治疗，仍有一些患者发生缺血性事件。血液生物标志物有望有助于轻度中风和TIA的诊断、风险分层及个体化治疗。该领域正在进行一些研究。本综述旨在强调用于诊断的潜在生物标志物以及有助于预测未来中风风险和选择治疗方法的生物标志物。
